Novartis subsidiary Sandoz's antibiotics efforts bear fruit during pandemic
Sandoz stands out from other pharmaceutical companies, as it produces both the active ingredients for antibiotics and the finished product. This is a strategy that served the company well during the pandemic, says Chief Business Officer Carol Lynch.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
The pandemic has been a blessing and a curse for Sandoz's antibiotics business.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Global antimicrobial fund expands with USD 140m and CEO
For subscribers
